Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the ...
Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Even though Pfizer Inc.'s ( NYSE:PFE ) recent earnings release was robust, the market didn't seem to notice. We ...
Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus ...
Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...
Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...
The market for Bavencio (avelumab), the checkpoint inhibitor co-developed by Pfizer (NYSE: PFE) and Merck KGaA (MRK: DE), ...
We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...
StockStory.org on MSN3d
3 Reasons PFE is Risky and 1 Stock to Buy InsteadPfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain.
Essex Investment Management Co. LLC cut its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 16.0% in the fourth quarter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback